<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ETANERCEPT</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ETANERCEPT</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Moderate to severe active rheumatoid arthritis (alone or in combination with methotrexate) when the response to other disease-modifying antirheumatic drugs is inadequate</span>,
                <span class="indication">Severe, active, and progressive rheumatoid arthritis not previously treated with methotrexate</span>,
                <span class="indication">Active and progressive psoriatic arthritis inadequately responsive to other disease-modifying antirheumatic drugs</span>,
                <span class="indication">Severe ankylosing spondylitis inadequately responsive to conventional therapy</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                25 mg twice weekly, alternatively 50 mg once weekly.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe plaque psoriasis either refractory to at least 2 standard systemic treatments and photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                25 mg twice weekly for up to 24 weeks, alternatively 50 mg once weekly for up to 24 weeks, discontinue if no response after 12 weeks.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid&#8212;limited information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution in moderate to severe alcoholic hepatitis.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active infection</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>uncommon:</strong> Interstitial lung disease, new onset or worsening psoriasis, rash, skin cancer, uveitis,
              </p>
              <p>
                <strong>rare:</strong> Demyelinating disorders, lymphoma, seizures, Stevens-Johnson syndrome, vasculitis,
              </p>
              <p>
                <strong>veryRare:</strong> Toxic epidermal necrolysis,
              </p>
              <p>
                <strong>notKnown:</strong> Abdominal pain, anaemia, antibody formation, aplastic anaemia, appendicitis, blood disorders, cutaneous ulcer, depression, diabetes mellitus, fever, gastritis, headache, hypersensitivity reactions, inflammatory bowel disease, injection-site reactions, leucopenia, leukaemia, lupus erythematosus-like syndrome, macrophage activation syndrome, malignancy, nausea, oesophagitis, pancytopenia, pruritus, solid tumours, thrombocytopenia, vomiting, worsening heart failure,
              </p>
        
        
            <section class="advice">
              <p>Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Blood disorders</h3>
              <p>Patients and their carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Tuberculosis</h3>
              <p>Patients and their carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.</p>
            </section>
            <section class="patientResources">
              <p>An alert card should be provided.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA103</h3>
              <p outputclass="title">Etanercept and efalizumab for plaque psoriasis in adults (July 2006)</p> <p>Etanercept is recommended for severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Etanercept should be withdrawn if the response is not adequate after 12 weeks.</p><xref format="html" href="http://www.nice.org.uk/TA103">www.nice.org.uk/TA103</xref>
                <a href="http://www.nice.org.uk/TA103" target="_blank">www.nice.org.uk/TA103</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA130</h3>
              <p outputclass="title">Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007)</p> <p>Etanercept is an option for the treatment of adults with active rheumatoid arthritis who have failed to respond to at least 2 disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contra-indicated). TNF-&#945; inhibitors should be given in combination with methotrexate; however, when methotrexate cannot be used because of intolerance or contra-indications, etanercept can be given as monotherapy.</p> <p>Etanercept should be withdrawn if response is not adequate within 6 months. Response to treatment should be monitored at least every 6 months in patients who respond initially; treatment should be withdrawn if response is not maintained. An alternative TNF-&#945; inhibitor may be considered for patients in whom treatment is withdrawn because of intolerance before the initial 6-month assessment of efficacy.</p> <p>Use of TNF-&#945; inhibitors for the treatment of severe, active, and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other DMARDs is not recommended.</p><xref format="html" href="http://www.nice.org.uk/TA130">www.nice.org.uk/TA130</xref>
                <a href="http://www.nice.org.uk/TA130" target="_blank">www.nice.org.uk/TA130</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA143</h3>
              <p outputclass="title">Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008)</p> <p>Etanercept is a treatment option for adults with severe active ankylosing spondylitis whose disease satisfies specific criteria for diagnosis where there is confirmation of sustained active spinal disease, and where treatment with two or more NSAIDs taken sequentially at maximum tolerated or recommended doses for 4 weeks has failed to control symptoms.</p> <p>Response to etanercept treatment should be assessed at 12-week intervals and continued only if response is adequate. If response to treatment is not maintained, a repeat assessment should be made after a further 6 weeks and treatment discontinued if there is an inadequate response. Patients who are intolerant of etanercept during the initial 12 weeks may receive adalimumab. However an alternative TNF-a inhibitor is not recommended in patients who fail to respond initially or fail to maintain an adequate response.</p> <p>See full NICE guidance for specific criteria to diagnose severe active ankylosing spondylitis, confirm sustained active spinal disease, and assess response to treatment.</p><xref format="html" href="http://www.nice.org.uk/TA143">www.nice.org.uk/TA143</xref>
                <a href="http://www.nice.org.uk/TA143" target="_blank">www.nice.org.uk/TA143</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA195</h3>
              <p outputclass="title">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)</p> <p>Etanercept, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. In patients who cannot use methotrexate because of intolerance or contra-indications, etanercept can be given as monotherapy. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.</p><xref format="html" href="http://www.nice.org.uk/TA195">www.nice.org.uk/TA195</xref>
                <a href="http://www.nice.org.uk/TA195" target="_blank">www.nice.org.uk/TA195</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA199</h3>
              <p outputclass="title">Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010)</p> <p>Etanercept is recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination).</p> <p>Etanercept should be discontinued if there is an inadequate response at 12 weeks.</p><xref format="html" href="http://www.nice.org.uk/TA199">www.nice.org.uk/TA199</xref>
                <a href="http://www.nice.org.uk/TA199" target="_blank">www.nice.org.uk/TA199</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Children should be brought up to date with current immunisation schedule before initiating therapy
          </li>
          <li>
            development of malignancy
          </li>
          <li>
            diabetes mellitus
          </li>
          <li>
            heart failure (risk of exacerbation)
          </li>
          <li>
            hepatitis B virus&#8212;monitor for active infection
          </li>
          <li>
            hepatitis C infection (monitor for worsening infection)
          </li>
          <li>
            history of blood disorders
          </li>
          <li>
            history of malignancy
          </li>
          <li>
            history or increased risk of demyelinating disorders
          </li>
          <li>
            predisposition to infection (avoid if predisposition to septicaemia)
          </li>
          <li>
            significant exposure to herpes zoster virus&#8212;interrupt treatment and consider varicella&#8211;zoster immunoglobulin
          </li>
        </ul>
        <ul>
          <li>
            <p>Active tuberculosis should be treated with standard treatment for at least 2 months before starting etanercept. Patients who have previously received adequate treatment for tuberculosis can start etanercept but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting etanercept. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with etanercept.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Manufacturer advises effective contraception required during treatment and for 3 weeks after last dose.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor for skin cancer before and during treatment, particularly in those at risk (including patients with psoriasis or a history of PUVA treatment).</p>
            </section>
      </section>






      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
                <h3>Tuberculosis</h3>
              <p>Patients should be evaluated for tuberculosis before treatment.</p>
            </section>
      </section>





      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ETANERCEPT</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76730"><a href="../medicinalForm/PHP76730.html" data-target="#PHP76730" data-action="load">Solution for injection</a></div>
            <div id="PHP76738"><a href="../medicinalForm/PHP76738.html" data-target="#PHP76738" data-action="load">Powder and solvent for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
